Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

NCT05687279 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infection

Interventions

BIOLOGICAL: RSVt Vaccine
OTHER: Control Group

Sponsor

Sanofi Pasteur, a Sanofi Company